Back to top

Intellia Therapeutics (NTLA) Looks Good: Stock Gains 9.9%
October 14, 2016

Read MoreHide Full Article

Intellia Therapeutics Inc. (NTLA - Free Report) was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 33.5% in the past one-month time frame.

The company has seen no estimate revisions over the past 7 days, while the Zacks Consensus Estimate remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Intellia Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

A better-ranked stock in the Med-Biomed/Gene industry is Amarin Corporation plc (AMRN - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here

Is NTLA going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Amarin Corporation PLC (AMRN) - free report >>

Intellia Therapeutics, Inc. (NTLA) - free report >>


More from Zacks Tale of the Tape

You May Like